Human Botulism Immune Globulin for the Treatment of Infant Botulism

Abstract
We created the orphan drug Human Botulism Immune Globulin Intravenous (BIG-IV), which neutralizes botulinum toxin, and evaluated its safety and efficacy in treating infant botulism, the intestinal-toxemia form of human botulism.